Related Experiment Video
Updated: Jun 18, 2026

Bacterial Artificial Chromosomes: A Functional Genomics Tool for the Study of Positive-strand RNA Viruses
Published on: December 29, 2015
Growth, Pathogenesis, and Serological Characteristics of the Japanese Encephalitis Virus Genotype IV Recent Strain
Shigeru Tajima1, Takahiro Maeki1, Eri Nakayama1
1Department of Virology 1, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo 162-8640, Japan.
Abstract:
Genotype IV Japanese encephalitis (JE) virus (GIV JEV) is the least common and most neglected genotype in JEV. We evaluated the growth and pathogenic potential of the GIV strain 19CxBa-83-Cv, which was isolated from a mosquito pool in Bali, Indonesia, in 2019, and serological analyses were also conducted. The growth ability of 19CxBa-83-Cv in Vero cells was intermediate between that of the genotype I (GI) strain Mie/41/2002 and the genotype V (GV) strain Muar, whereas 19CxBa-83-Cv and Mie/41/2002 grew faster than Muar in mouse neuroblastoma cells. The neuroinvasiveness of 19CxBa-83-Cv in mice was higher than that of Mie/41/2002 but lower than that of Muar; however, there were no significant differences in neurovirulence in mice among the three strains. The neutralizing titers of sera from 19CxBa-83-Cv- and Mie/41/2002-inoculated mice against 19CxBa-83-Cv and Mie/41/2002 were similar, whereas the titers against Muar were lower than those of the other two viruses. The neutralizing titers of JE vaccine-inoculated mouse pool serum against 19CxBa-83-Cv and Muar were significantly lower than those against Mie/41/2002. The neutralizing titers against the three viruses were similar in three out of the five serum samples from GI-infected JE patients, although the titers against Mie/41/2002 were higher than those against 19CxBa-83-Cv and Muar in the remaining two sera samples. In summary, we identified the basic characteristics of 19CxBa-83-Cv, but further studies are needed to better understand GIV JEV.
Insights
Genotype IV Japanese encephalitis virus (GIV JEV), a neglected strain, shows intermediate growth and varying neuroinvasiveness. Further research is needed to fully understand GIV JEV characteristics and its implications for Japanese encephalitis.
Area of Science:
- Virology
- Immunology
- Infectious Diseases
Background:
- Genotype IV Japanese encephalitis virus (GIV JEV) is the least common and most neglected genotype.
- Understanding GIV JEV's characteristics is crucial for disease control and vaccine development.
Purpose of the Study:
- To evaluate the growth and pathogenic potential of the GIV strain 19CxBa-83-Cv isolated in Indonesia.
- To conduct serological analyses of GIV JEV and its interaction with existing Japanese encephalitis virus (JEV) strains and vaccines.
Main Methods:
- In vitro cell culture growth assays (Vero and mouse neuroblastoma cells).
- In vivo mouse models to assess neuroinvasiveness and neurovirulence.
- Serological analysis of neutralizing antibody titers against different JEV genotypes.
Main Results:
- The GIV JEV strain 19CxBa-83-Cv exhibited intermediate growth in Vero cells and faster growth in mouse neuroblastoma cells compared to genotype V (GV) strain Muar.
- Neuroinvasiveness of 19CxBa-83-Cv in mice was higher than genotype I (GI) strain Mie/41/2002 but lower than Muar; neurovirulence was similar across strains.
- Neutralizing antibody titers varied, with lower responses against the GV strain Muar and reduced efficacy of JE vaccines against GIV JEV and GV strains compared to GI strain.
Conclusions:
- The GIV JEV strain 19CxBa-83-Cv possesses distinct growth and pathogenic characteristics.
- Current JE vaccines may have reduced efficacy against GIV JEV and GV strains, highlighting the need for updated or broader-spectrum vaccines.
- Further research is essential to fully elucidate the epidemiology and public health impact of GIV JEV.
More Related Videos
Related Concept Videos
Viral Meningitis
Arboviral Encephalitis
Cytomegalovirus Disease
Bacterial Meningitis II: Pathophysiology
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology

